MedTrace Logo

Chemo-radiotherapy as Main Treatment Strategy for Rectal Cancer. Can we Provide a More Precise and Effective Treatment

NCT03619668 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2023-08-03

No results posted yet for this study

Summary

The purpose of this project is to obtain important information about the tumour and surrounding organs during preoperative chemo-radiotherapy for patients with adenocarcinoma of the rectum. The knowledge generated in this project has the potential to make future radiotherapy treatments (RT) of rectal cancer patients more precise, with less side effects. This could lead the way to make chemo-radiotherapy the main treatment modality and spare a large group of patients from the risk of severe complications after surgery. Specifically, we aim to obtain:

* A characterization of systematic and random changes in position and shape of tumours and surrounding organs during RT.
* A patient-specific pre-treatment characterization of random uncertainties in position and shape of the tumour during radiotherapy. This will be used to create and assess an individual, patient-specific treatment strategy, with the possibility to implement an adaptive RT strategy using the information obtained from the MRI-scans during treatment.
* Information about treatment response and local toxicity from morphological and functional data before, during and after CRT.

Conditions

  • Rectal Cancer
  • Rectal Adenocarcinoma
  • Locally Advanced Malignant Neoplasm

Sponsors & Collaborators

  • Aalborg University Hospital

    lead OTHER

Principal Investigators

  • Dennis T. Arp, Medical Physicist · Department of Medical Physics, Oncology, Aalborg University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-29
Primary Completion
2022-02-01
Completion
2025-03-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03619668 on ClinicalTrials.gov